Alexza Pharmaceuticals Inc.
|
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Starting to look like a great short, no way it should up 50% on less than $50k in trades. Might the ole classic gap and trap
Was only about $14k in after hours sales. It's starting to look like a fake oit
I sold all my shares such a dope...look who is scooping all the after hours shares.
can almost guarantee more news today something is UP
The way it's being bid up on such low volume it'll probably crash quickly
HOLY COW this is going to be $5.00 plus tomorrow.
crazy news as I sold most of my shares last week.
going to by more at open...watch 3 dollars after hours....hope I can get for $3 tomorrow.
my firm does not have after hour
This was an interesting move on Alexza's part. I'll be curious to see how the market reacts. Generally, the market has hated anything "interesting" the company has done. Hopefully more information will be forth coming at Thursday's 3rd Quarter meeting.
Yes, I agree the potential to have the Stacatto system in an outpatient setting would be a real competitive advantage and signal high public confidence in the device to produce a reliable drug particle size distribution. This must surely take the interest of big pharma for its potential to outcompete their rivals in drug delivery.
I consider myself a long time holder too and significantly underwater but never sold a share!!
We seem to have a new strategy already with Alexza seeing Teva as a weak link in their US sales when compared to the performance of Groupo Ferrer in the EU. I hope they quickly improve US sales with a new partner.
MOUNTAIN VIEW, Calif., Oct. 30, 2015 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (ALXA) announced today that it plans to reacquire the U.S. rights for ADASUVE® (loxapine) inhalation powder from Teva Pharmaceuticals USA, Inc., a subsidiary of Teva Pharmaceutical Industries Ltd., with an estimated target completion date of January 1, 2016. Alexza and Teva also plan to restructure the obligations under the outstanding note from Teva. Alexza and Teva are working on a transition agreement to continue product availability to patients and health care providers after the return of the rights to Alexza.
"ADASUVE is an effective product. There are considerable challenges in launching a hospital product, especially one as complex as ADASUVE. We appreciate the efforts that Teva has made to date and are looking forward to continuing to build the ADASUVE brand," said Thomas B. King, Alexza President and CEO. "We remain confident in ADASUVE's long-term commercial prospects and plan to work with Teva to effect a smooth transition. It is our intention to work diligently in 2016 to identify a new U.S. commercial partner for ADASUVE."
I am keen see how the numbers are looking in the ER next week.
I think the "allow the use of the product in the outpatient setting" is key.
Not sure what the new "strategy" will be but in the past this has never led to increased shareholder value (very long time holder here).
DOWN BUT NOT OUT: Solid Press Release
http://www.prnewswire.com/news-releases/ferrer-and-alexza-pharmaceuticals-provide-update-on-adasuve-european-and-latin-american-commercial-activities-300159392.html
It has been a very bumpy road so far but there is sustained and clear product acceptance by end users, an increasing foothold in the medical community (peer reviewed publications) followed by ongoing market expansion expansion.
Key points:
"In the past year, there have been five publications in peer-reviewed journals addressing both clinical experience with ADASUVE and the pharmacoeconomics of using ADASUVE, highlighting the costs and burden of established habits of dealing with agitated patients."
ADASUVE saves time and money, helping overburdened medical systems. Patients suffer less. Hospital staff are safer.
Bonus label expansion potential:
"Ferrer recently met with the EU regulatory authorities to explore the potential modification of the ADASUVE label in Europe to allow the use of the product in the outpatient setting."
Sales are thus expected to shift higher. Costs are expected to move lower as production schedule can wind down. EPS can thus gain significantly over the next year. Possible new company strategy can be an additional catalyst for stock price appreciation.
MOUNTAIN VIEW, Calif., Sept. 28, 2015 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (ALXA) announced today that it has retained Guggenheim Securities, LLC to assist in exploring strategic options to enhance stockholder value, including a possible sale or disposition of one or more corporate assets, a strategic business combination, partnership or other transactions.
"We continue to see long-term opportunities for our Staccato inhaled drug technology, especially in light of the positive responses from physicians and patients who have used our lead product, ADASUVE," said Thomas B. King, President and CEO of Alexza. "Our Board is focused on evaluating additional options that may enhance or accelerate the value that we believe is inherent in an approved technology-platform product, which has been successfully screened for numerous drugs as a novel delivery method that enables pharmacokinetics similar to intravenous administration. Given this strength of our Staccato technology, we believe now is the appropriate time to explore strategic alternatives."
Repeat: "Our Board is focused on evaluating additional options that may enhance or accelerate the value that we believe is inherent". I hope for action on this soon. Shares are undervalued and I am significantly underwater for years but not letting go. Hopefully with the manufacturing shutdown plan in place, the stock will recover as running costs dramatically reduce....but the "inherent value" is another issue to reach a level for a real return on investment. There must be some interested parties in this proven technology given positive real world feedback.
remember this was $5.00 caliing.45-bottom-and-will-sit-there
Sounds like some key board members left the company. Don't know why these idiots on the L2 are trying so hard to keep this up. Guessing they are expecting a short squeeze. GL bc this thing is going to pennies!
When this breaks $1/share this will fall off the chart$$$$ Traders love those round numbers lol
poor financials, technical support broke at 1.22/share, lack of buying could = gap DOWN
Could GAP DOWN HERE SELL SELL SELL!
Could GAP DOWN HERE SELL SELL SELL!
Wow, This one should keep falling below $1. No income and super bad 10Kfiling. Will be interesting seeing how far this falls...
Hey MacD! good man.
I do believe this one is in play. Might take a few weeks to reset but has potential.
Someone left the cap off the bottle. Losing fizz today.
$ALXA recent news/filings
bullish
## source: finance.yahoo.com
Fri, 08 Aug 2014 13:55:54 GMT ~ Alexza Pharmaceuticals Announces the Launch of ADASUVE® (inhalation powder, loxapine) in Guatemala
[at noodls] - MOUNTAIN VIEW, Calif., Aug. 8, 2014 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today announced that ADASUVE® inhalation powder, pre-dispensed (loxapine) is now available in Guatemala. ...
read full: http://www.noodls.com/view/01B9DBF7E93F91A4B8DF4EF2F977A4BDC106D811
*********************************************************
Fri, 08 Aug 2014 13:00:00 GMT ~ Alexza Pharmaceuticals Announces the Launch of ADASUVE® (inhalation powder, loxapine) in Guatemala
[PR Newswire] - MOUNTAIN VIEW, Calif., Aug. 8, 2014 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (ALXA) today announced that ADASUVE® inhalation powder, pre-dispensed (loxapine) is now available in Guatemala. This approval represents the first ADASUVE approval in Latin America for Ferrer and Alexza. Ferrer is Alexza's commercial partner for ADASUVE in the EU, Latin America and Commonwealth of Independent States countries. Ferrer introduced ADASUVE during a psychiatric medical meeting in Guatemala, hosted by Congreso National de Psiquiatria de Guatemala, held in Guatemala City, August 7 - 8, 2014. During the meeting, Ferrer hosted a symposium on agitation, entitled "ADASUVE: una innovacion terapeutica en el tratamiento de la agitacion" or "ADASUVE: A therapeutic innovation in the treatment of agitation."
read full: http://finance.yahoo.com/news/alexza-pharmaceuticals-announces-launch-adasuve-130000916.html
*********************************************************
Thu, 07 Aug 2014 21:00:00 GMT ~ Alexza Pharmaceuticals Inc Earnings Call scheduled for 5:00 pm ET today
read full: http://biz.yahoo.com/cc/9/143839.html
*********************************************************
Thu, 07 Aug 2014 20:12:03 GMT ~ ALEXZA PHARMACEUTICALS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
read full: http://biz.yahoo.com/e/140807/alxa8-k.html
*********************************************************
Thu, 07 Aug 2014 20:05:00 GMT ~ Alexza Reports 2014 Second Quarter Financial Results
[PR Newswire] - MOUNTAIN VIEW, Calif., Aug. 7, 2014 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today reported financial results for the quarter ended June 30, 2014. The net loss for the second quarter ...
read full: http://finance.yahoo.com/news/alexza-reports-2014-second-quarter-200500555.html
*********************************************************
$ALXA charts
basic chart ## source: stockcharts.com
basic chart ## source: eoddata.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$ALXA company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/ALXA/company-info
Ticker: $ALXA
OTC Market Place: Not Available
CIK code: 0001344413
Company name: Alexza Pharmaceuticals, Inc.
Incorporated In: DE, USA
Business Description:
$ALXA share structure
## source: otcmarkets.com
Market Value: $69,973,402 a/o Aug 08, 2014
Shares Outstanding: 17,320,149 a/o Apr 30, 2014
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.0001
$ALXA extra dd links
Company name: Alexza Pharmaceuticals, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/ALXA/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/ALXA/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=ALXA+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=ALXA+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=ALXA+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/ALXA/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/ALXA/news - http://finance.yahoo.com/q/h?s=ALXA+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/ALXA/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/ALXA/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/ALXA/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/ALXA/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/ALXA/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/ALXA/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/ALXA/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/ALXA/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=ALXA+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/ALXA
DTCC (dtcc.com): http://search2.dtcc.com/?q=Alexza+Pharmaceuticals%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Alexza+Pharmaceuticals%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Alexza+Pharmaceuticals%2C+Inc.&x=0&y=0
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/ALXA/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/ALXA
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/ALXA/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/ALXA/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/ALXA/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001344413&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/ALXA/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/ALXA/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/ALXA/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/ALXA/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=ALXA&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=ALXA
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/ALXA/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=ALXA+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=ALXA+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=ALXA
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=ALXA
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=ALXA+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/ALXA/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=ALXA+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/ALXA.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=ALXA
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/ALXA/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/ALXA/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/ALXA/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/ALXA/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/ALXA
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/ALXA
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/ALXA:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=ALXA
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=ALXA
$ALXA DD Notes ~ http://www.ddnotesmaker.com/ALXA
This is odd.....even for Alxa. What's with the sudden ramp up in volume at ~15:00 (3:00 p.m.)? I mean a few thousand shares till then and suddenly ~80K shares....Very unusual. And it's staying in the green...Curiouser and curiouser.
Worst performing stock I've held up to now. Nothing but decent news and it continues the long spiral down.....Not to mention the impact of the current biotech sell-off. At these prices I've thrown in some shares in my 401K versus my "mad money" fund where I've taken the majority of my losses. The odd thing is the average brokerage recommendation (ABR)is buy...but the reports say sell. I guess on the bright side; no dilution, restarting pipeline, some TEVA progress (as much as I can tell), shopping for partners for non-allocated territories (Asia, etc.)should show some results in the next 60-90 days (I'm guessing here). I've held this too long now and since I don't need the funds for anything else I might as well hang in for a bit longer.
Wow. Just checking in here after not having checked in over a year. Sigh. I feel your pain SciFi1....this stock is definitely in a dead bedroom situation and is finally starting to make its spouse suspicious with the, "I'm too tired" excuse a few too many times.
GLTU
Taking a beating here. Looks like just about everyone else is too. Picked up a few more shares at $4.03. About time (past time) for a decent PR here....Of course ALXA stock always goes down on PR (good or bad).
Very kind of you.
Let me fix that for you:
"I'm xxxxxxxxxxx praying it's the partnership deal....But, this being Alexza.......dilution is always a xxxxxxxxxxxxx reality."
No partnership deal coming for the next pipeline drug. Unless it is a cure for cancer, it just won't happen. Dilution is next.
I'm anticipating it's the partnership deal....But, this being Alexza.......dilution is always a possibility.
Yes it has been a quiet run up, along with a quite (soft) launch by TEVA. Nothing spectacular on any given day just "below the radar" activity. I'm cautiously encouraged.
ALXA is simply preparing to dilute. They have no cash for advancing any pipeline drugs.
There are only two realistic ways they do NOT dilute:
1. Adasuve sales are so stupendous out the gate that cash is rolling in hand over fist.
2. Anoher biotech company partners with them and funds the next pipeline drug.
Dilution is inevitable here.
No news is good news for ALXA? Haven't been back to this board in a while. Very little news (good or bad) recently. I think this quiet (soft) launch and institutional buying is encouraging. Two (2) weeks (06 March) till the year end reporting so, there may be a bit of a run up. I believe the ALXA "International" leadership has been in place for long enough we may begin to see some of the other areas (Japan, China, Canada...etc) make deals (probably another 3 months out).
Anybody else make money on PRAN (I got in at ~$2.00)? Heck of dueling "Experts" battle going on there. Alzheimer's results due our in March for them....Could be a very good month for me (about time).
Full disclosure: I'm in ALXA at ~$6.50.....and I've been VERY patient with this stock.
Teva To Price Alexza's New Drug Adasuve At $145 Per Dose In The U.S.
From Seeking Alpha
http://seekingalpha.com/article/1992271-teva-to-price-alexzas-new-drug-adasuve-at-145-per-dose-in-the-u-s?source=kizur_seekingalpha
Alexza Pharmaceuticals Announces Ferrer's Launch of ADASUVE® (Staccato® Loxapine) in Spain Triggering a $1 Million Milestone Payment
MOUNTAIN VIEW, Calif., Jan. 21, 2014 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (ALXA) today announced that ADASUVE® inhalation powder, pre-dispensed (Staccato® loxapine) is now available in Spain through Grupo Ferrer Internacional, S.A. (Ferrer). Ferrer is Alexza's commercial partner for ADASUVE in the European Union (EU), Latin America, Russia and the CIS countries. In conjunction with this commercial introduction of ADASUVE in Spain by Ferrer, Alexza will receive a milestone payment of $1 million.
(Logo: http://photos.prnewswire.com/prnh/20140121/SF49110LOGO)
"Given that Ferrer is one of the largest Spanish pharmaceutical companies, launching ADASUVE in our home market is an important milestone," said Antoni Villaro, Chief Operating Officer of Ferrer. "We expect to demonstrate Ferrer's commitment to commercial excellence and hope to serve as a reference for all other markets."
"Ferrer has consistently demonstrated a high degree of focus, commitment and collaboration in introducing ADASUVE to physicians who are seeking new therapeutic options for the treatment of agitation associated with bipolar disorder or schizophrenia," said Thomas B. King, President and CEO of Alexza. "With the launch of ADASUVE in Spain, we are pleased with how Ferrer is continuing to execute on its planned commercial launch across Europe."
Alexza received marketing authorization for ADASUVE from the European Commission in February 2013. ADASUVE is the first inhalation therapy for the rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder authorized for marketing in the EU. Alexza and Ferrer estimate that as many as 8 million adults in the EU suffer from schizophrenia or bipolar disorder1. Agitation is a common symptom for these patients2, characterized by feelings of distress, anxiety and loss of control. The marketing authorization for ADASUVE requires that patients receive regular treatment immediately after control of acute agitation symptoms. It also requires that ADASUVE be administered only in a hospital setting under the supervision of a healthcare professional and that short-acting beta-agonist bronchodilator treatment should be available for treatment of possible severe respiratory side-effects, such as bronchospasm.
Alexza and Ferrer established a collaboration agreement in October 2011. Under the terms of this agreement, Alexza is the exclusive supplier of ADASUVE and is responsible for all aspects of manufacture of the product. Ferrer is responsible for commercial activities and is expected to launch ADASUVE in additional EU countries throughout 2014.
About ADASUVE (Staccato loxapine)
ADASUVE combines Alexza's proprietary Staccato system with loxapine, an antipsychotic medicinal product. The Staccato system is a hand-held inhaler that delivers a drug aerosol to the deep lung that results in intravenous-like pharmacokinetics and rapid systemic effects.
ADASUVE has been approved for marketing in the United States by the U.S. Food and Drug Administration and in the EU by the European Commission. The authorization for ADASUVE in the EU differs from that in the U.S., with respect to the indication statement, dose regimen, available dose strengths, and risk mitigation and management plans.
For more information about ADASUVE, including the Summary of Product Characteristics and Patient Information Leaflet approved in the EU, please visit: www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002400/human_med_001618.jsp&mid=WC0b01ac058001d124. For the full prescribing information including boxed warnings for the U.S., please visit www.adasuve.com.
About Ferrer
Founded in 1959, Ferrer is a privately-held European R&D-based pharmaceutical company headquartered in Barcelona. It is active in the pharmaceutical, health, fine chemicals and food sectors in Europe, Latin America, Africa, the Middle East, Asia and the United States. In total, Ferrer's human healthcare products are commercialized in more than 90 countries, through 27 international affiliates (including joint ventures) and 70 partners and distributors.
Ferrer carries out activities throughout the full pharmaceutical value chain, from R&D to international marketing, including fine chemical development and the manufacturing of both raw materials and finished pharmaceuticals. Its research centers in Spain and Germany, and manufacturing sites in Europe and Latin America cover the pharmaceutical, diagnostics, vaccine, fine chemical, food and feed sectors.
Ferrer is Alexza's commercial partner for ADASUVE in Europe, Latin America, Russia and the Commonwealth of Independent States countries.
For more information, visit www.ferrergrupo.com
About Alexza Pharmaceuticals, Inc.
Alexza Pharmaceuticals is focused on the research, development and commercialization of novel, proprietary products for the acute treatment of central nervous system conditions. Alexza's products are based on the Staccato system, a hand-held inhaler designed to deliver a drug aerosol to the deep lung, providing rapid systemic delivery and therapeutic onset, in a simple, non-invasive manner.
ADASUVE (Staccato loxapine) is Alexza's first commercial product, which was approved by the U.S. Food and Drug Administration in December 2012 and by the European Commission in February 2013. Teva Pharmaceuticals USA, Inc. is Alexza's commercial partner for ADASUVE in the U.S. Grupo Ferrer Internacional, S.A. is Alexza's commercial partner for ADASUVE in Europe, Latin America, Russia and the Commonwealth of Independent States countries.
http://finance.yahoo.com/news/alexza-pharmaceuticals-announces-ferrers-launch-140500661.html
Teva Adasuve launch soon? While many are predicting/anticipating launch in January, I'm not sure this is very high probability given the late (January) hires by TEVA. Probably need to give the new hires a bit of time to get on-board. February? Maybe....March more likely. Anyway, only 11 more days in January till we find out. Let's just say I haven't had too many pleasant (ahead of schedule) surprises with this stock.
~$157 price for Adasuve? Not sure if that's good or bad but considering I paid $186 for a shingles vaccine Friday (not covered by my insurance) probably not totally out of whack.
I'm actually more curious about when we'll hear about deals in Asia and Canada (etc). This could provide a nice bump in stock price. This may have to wait till after the Adasuve launch in the US......It's what I'd do to (hopefully) get a better deal; bootstrapping off the TEAV launch.
Haven't been back to this board in a while...Hope you're all doing well.
Ok?!?!?
Execs get BIG with a Capitol "B" raises as the company achieved 92.5% of year end objectives...
Is that what drove up the price???
If they met objectives... Hopefully that will be reflected in the pps
Any news out?
What happened at EOD???
Took off BIG TIME!!!
At 3:49 it was at 4.59, then in after hours, traded @ 4.83!!!
Anyone?
If King and execs would keep their hands out of the cookie jar then the stock would be higher. Over $1M/year for King's inept services.
The funniest (most interesting?) comment was King didn't understand why the stock price wasn't higher either...
King musta said something right for once.
Transcript of Piper meeting:
http://seekingalpha.com/article/1875291-alexza-pharmaceuticals-ceo-presents-at-piper-jaffray-healthcare-conference-transcript?source=yahoo
Some nice anecdotal (meaning take it with a grain of salt) stories from Germany. Stock price still on hold....
Teva's CEO (Levin) resigns/is fired. An Alexza surprise but, this one was not exactly self inflicted. However, being Alexza's US partner....we'll probably see some collateral damage to the Alexza stock price over the next weeks....purely a knee jerk reaction I'd think. Never a dull moment for this stock.
Leveling around the 5.10+/- for the past month. Certainly better than the sub-5.00 previously. Very quiet on the PR front. Next earnings results due 04 November (14 working, 20 calendar days). Nice opportunity in the next couple of weeks for announcement of another deal in the as yet unallocated countries/regions. Don't really expect much from the German sales release.
Or, there might be some unexpected "Alexza Weirdness".....It's been known to happen. But, I think the company has matured and gained some financial stability to put it a bit past that.
Followers
|
57
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
3195
|
Created
|
06/29/07
|
Type
|
Free
|
Moderators |
Alexza Pharmaceuticals Inc.
Alexza Pharmaceuticals is a rapidly emerging pharmaceutical company focused on the research, development and commercialization of novel proprietary products for the acute treatment of central nervous system, or CNS conditions. All of our product candidates are based on our proprietary technology, the Staccato® system. The Staccato system vaporizes excipient-free drugs to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery. Because of the ideal particle size of the aerosol, the pure drug is quickly absorbed through the deep lung into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous (IV) administration but with greater ease, patient comfort and convenience.Alexza's lead program is ADASUVE™ (Staccato loxapine or AZ-004), being developed for the acute treatment of agitation in patients with schizophrenia or bipolar disease. During 2011, Alexza resubmitted the ADASUVE NDA and the ADASUVE MAA in Europe. Alexza has a U.S. PDUFA goal date for ADASUVE of February 4, 2012.Staccato nicotine (Preclinical) |
Thomas B. King President, Chief Executive Officer Thomas B. King has served as our President, Chief Executive Officer and a member of our Board since June 2003. From September 2002 to April 2003, Mr. King served as President, Chief Executive Officer and a member of the board of directors of Cognetix, Inc., a biopharmaceutical development company. From January 1994 to February 2001, Mr. King held various senior executive positions, including President and Chief Executive Officer from January 1997 to October 2000, and was a member of the board of directors at Anesta Corporation, a publicly traded pharmaceutical company, until it was acquired by Cephalon, Inc., a publicly traded biopharmaceutical company. Mr. King received an M.B.A. from the University of Kansas and a B.A. in chemistry from McPherson College. |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |